Medigene AG (MDG1.DE)
EUR 1.08
(-1.64%)
EUR 1.08
(-1.64%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.39 Million EUR | -89.81% |
| 2022 | 29.26 Million EUR | 221.48% |
| 2021 | 9.1 Million EUR | 22.07% |
| 2020 | 7.45 Million EUR | -27.24% |
| 2019 | 10.24 Million EUR | 48.43% |
| 2018 | 6.9 Million EUR | -29.21% |
| 2017 | 9.75 Million EUR | 16.86% |
| 2016 | 8.34 Million EUR | 46.31% |
| 2015 | 5.7 Million EUR | -51.23% |
| 2014 | 11.69 Million EUR | 99.73% |
| 2013 | 5.85 Million EUR | 16.35% |
| 2012 | 5.03 Million EUR | 35.94% |
| 2011 | 3.7 Million EUR | 145.07% |
| 2010 | 1.51 Million EUR | -81.07% |
| 2009 | 7.98 Million EUR | -37.03% |
| 2008 | 12.68 Million EUR | -70.07% |
| 2007 | 42.37 Million EUR | 1.14% |
| 2006 | 41.89 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.85 Million EUR | 64.65% |
| 2024 Q2 | 1.12 Million EUR | -39.29% |
| 2023 Q3 | 1.12 Million EUR | 1.67% |
| 2023 FY | 2.98 Million EUR | -89.81% |
| 2023 Q4 | 1.12 Million EUR | 0.0% |
| 2023 Q1 | 1.07 Million EUR | -55.33% |
| 2023 Q2 | 1.1 Million EUR | 3.27% |
| 2022 Q4 | 2.39 Million EUR | 0.0% |
| 2022 Q1 | 12.23 Million EUR | 297.22% |
| 2022 Q2 | 1.7 Million EUR | -86.06% |
| 2022 Q3 | 2.39 Million EUR | 40.53% |
| 2022 FY | 29.26 Million EUR | 221.48% |
| 2021 FY | 9.1 Million EUR | 22.07% |
| 2021 Q3 | 2.72 Million EUR | 38.83% |
| 2021 Q2 | 1.96 Million EUR | 7.22% |
| 2021 Q4 | 3.08 Million EUR | 13.13% |
| 2021 Q1 | 1.82 Million EUR | 183.25% |
| 2020 Q4 | -2.19 Million EUR | -244.68% |
| 2020 FY | 7.45 Million EUR | -27.24% |
| 2020 Q2 | 2.27 Million EUR | 23.71% |
| 2020 Q3 | 1.51 Million EUR | -33.16% |
| 2020 Q1 | 1.83 Million EUR | -50.2% |
| 2019 Q2 | 3.54 Million EUR | 106.17% |
| 2019 Q4 | 3.68 Million EUR | 183.04% |
| 2019 FY | 10.24 Million EUR | 48.43% |
| 2019 Q1 | 1.71 Million EUR | 499.3% |
| 2019 Q3 | 1.3 Million EUR | -63.19% |
| 2018 FY | 6.9 Million EUR | -29.21% |
| 2018 Q1 | 2.39 Million EUR | -30.5% |
| 2018 Q4 | -430 Thousand EUR | -119.09% |
| 2018 Q3 | 2.25 Million EUR | -16.28% |
| 2018 Q2 | 2.69 Million EUR | 12.59% |
| 2017 Q4 | 3.43 Million EUR | 72.47% |
| 2017 Q3 | 1.99 Million EUR | -6.47% |
| 2017 Q2 | 2.13 Million EUR | -2.6% |
| 2017 Q1 | 2.18 Million EUR | -9.62% |
| 2017 FY | 9.75 Million EUR | 16.86% |
| 2016 Q1 | 3.59 Million EUR | 189.61% |
| 2016 FY | 8.34 Million EUR | 46.31% |
| 2016 Q2 | 1.1 Million EUR | -69.31% |
| 2016 Q4 | 2.42 Million EUR | 97.07% |
| 2016 Q3 | 1.22 Million EUR | 11.42% |
| 2015 FY | 5.7 Million EUR | -51.23% |
| 2015 Q4 | 1.24 Million EUR | -20.6% |
| 2015 Q3 | 1.56 Million EUR | 5.47% |
| 2015 Q2 | 1.48 Million EUR | 4.51% |
| 2015 Q1 | 1.41 Million EUR | -68.73% |
| 2014 Q4 | 4.53 Million EUR | 142.46% |
| 2014 FY | 11.69 Million EUR | 99.73% |
| 2014 Q3 | 1.87 Million EUR | -40.27% |
| 2014 Q2 | 3.13 Million EUR | 44.75% |
| 2014 Q1 | 2.16 Million EUR | 20.77% |
| 2013 Q4 | 1.79 Million EUR | 6.29% |
| 2013 FY | 5.85 Million EUR | 16.35% |
| 2013 Q1 | 1.08 Million EUR | 3.43% |
| 2013 Q2 | 1.29 Million EUR | 19.24% |
| 2013 Q3 | 1.68 Million EUR | 30.12% |
| 2012 Q2 | 1.53 Million EUR | 14.43% |
| 2012 Q4 | 1.05 Million EUR | -4.72% |
| 2012 FY | 5.03 Million EUR | 35.94% |
| 2012 Q3 | 1.1 Million EUR | -28.35% |
| 2012 Q1 | 1.34 Million EUR | -51.41% |
| 2011 Q1 | 568 Thousand EUR | 108.77% |
| 2011 Q2 | 1.04 Million EUR | 83.1% |
| 2011 Q3 | 302 Thousand EUR | -70.96% |
| 2011 Q4 | 2.76 Million EUR | 815.89% |
| 2011 FY | 3.7 Million EUR | 145.07% |
| 2010 Q4 | -6.47 Million EUR | -501.67% |
| 2010 Q2 | 2.86 Million EUR | -17.89% |
| 2010 Q3 | 1.61 Million EUR | -43.79% |
| 2010 Q1 | 3.49 Million EUR | 175.91% |
| 2010 FY | 1.51 Million EUR | -81.07% |
| 2009 Q2 | 1.46 Million EUR | -46.72% |
| 2009 Q4 | 1.26 Million EUR | 0.64% |
| 2009 Q3 | 1.25 Million EUR | -14.07% |
| 2009 FY | 7.98 Million EUR | -37.03% |
| 2009 Q1 | 2.74 Million EUR | 0.0% |
| 2008 FY | 12.68 Million EUR | -70.07% |
| 2007 FY | 42.37 Million EUR | 1.14% |
| 2006 FY | 41.89 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| BioNTech SE | 3.21 Billion EUR | 99.864% |
| CureVac N.V. | -70.6 Million EUR | 106.219% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | 98.385% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | 98.385% |
| BRAIN Biotech AG | 30.12 Million EUR | 85.423% |
| Formycon AG | 23.3 Million EUR | 81.159% |
| Heidelberg Pharma AG | 6.6 Million EUR | 33.531% |